PHAXIAM and Technophage Collaborate on Phage Therapies
In a significant move in the realm of biopharmaceuticals, PHAXIAM Therapeutics and Technophage have announced a collaboration aimed at tackling severe and resistant bacterial infections. This partnership is particularly crucial given the alarming rise in antimicrobial-resistant infections across Europe.
A Comprehensive Approach to GMP Phages
PHAXIAM Therapeutics, known for its innovative treatments, is focusing on the development of individualized GMP phages, a type of therapy aimed at combating specific bacterial strains. The collaboration with Technophage, a specialist in GMP phage development, comes with the goal of expanding access to a portfolio of GMP phages that can be utilized by medical professionals.
Combating Antimicrobial Resistance
The collaboration is a direct response to the escalating challenge of antimicrobial resistance, which is responsible for over 70% of severe infections that are difficult to treat. By joining forces, the companies aim to enhance their GMP phages offerings and expedite the process of developing effective treatments for these resilient infections.
Aiming for 25 to 45 GMP Phages
One of the key objectives of this collaboration is to significantly increase the number of GMP phages available for individualized phage therapies (IPT). By 2026, the partnership aims to create a collection of 35 to 45 GMP phages targeting critical pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa. With such a diverse array of phages, the initiative seeks to provide targeted treatments for the most challenging infections.
Strategic Manufacturing Collaboration
PHAXIAM and Technophage will work closely on the manufacturing of GMP phages. This involves PHAXIAM producing and supplying Technophage with its GMP phages, while Technophage will reciprocate with its own phages. Such shared manufacturing ensures that both companies can optimize their resources and capabilities.
Commercialization Plans for Phage Therapies
The commercialization of this joint GMP phage portfolio will be managed by both parties within territories they define. Each company will leverage its strengths to capitalize on their respective assets, anticipating interactions with regulatory authorities and capitalizing on the growing clinical reach across major European markets.
Clinical Pathway Developments
Both organizations will continue their clinical pathways for their specific Phage Therapy Medicinal Products (PTMP). PHAXIAM will lead the GLORIA Phase II study, a landmark trial in the field of phage therapy, while Technophage will expedite its efforts with other ongoing trials focused on diabetic foot ulcers and ventilator-associated pneumonia.
Key Executive Insights
Thibaut du Fayet, CEO of PHAXIAM, elaborated on the partnership, describing it as a major leap forward in combating resistant infections. The integration of expertise from both companies is set to enhance the development of individualized therapies that hold promise for patients suffering from tough-to-treat infections.
Belief in Phage Therapy
Miguel Garcia, CEO of Technophage, expressed enthusiasm about the collaboration, emphasizing the company’s commitment to advancing phage therapy as a transformative treatment avenue. By joining forces with PHAXIAM, Technophage aims to facilitate patient access to high-quality, individualized phage-based treatments, underpinning a shared vision for the future of medicine.
About Technophage
Technophage is focused on creating innovative biologics designed to meet the therapeutic demands of unaddressed medical conditions. From infections to more complex health issues, their work is pivotal in shaping a future where effective treatments are accessible.
About PHAXIAM Therapeutics
PHAXIAM Therapeutics specializes in developing groundbreaking solutions for resistant bacterial infections. With a unique approach involving phages, PHAXIAM is committed to combating some of the most serious infections plaguing health systems today, guided by a vision to enhance patient care and outcomes.
Frequently Asked Questions
What is the main goal of the PHAXIAM and Technophage collaboration?
The primary aim is to enhance the development and access to individualized GMP phages that target severe resistant infections.
How many GMP phages do the companies aim to create by 2026?
The collaboration aspires to create a collection of 35 to 45 GMP phages targeting critical pathogens.
What role does the phagogram platform play in this partnership?
The phagogram platform is crucial for testing the susceptibility of bacterial strains, improving the development of effective phage therapies.
What types of infections are the focus of this collaboration?
The collaboration primarily targets severe and resistant bacterial infections, particularly those caused by critical pathogens.
Where is PHAXIAM Therapeutics listed?
PHAXIAM Therapeutics is listed on the Euronext regulated market in Paris.
